How often should nurses repeat blood pressure and glucose monitoring when cortisol excess is suspected before endocrine review?

Until specialist parameters are set, pair scheduled vitals with point-of-care or laboratory glucose checks if there is new confusion, polyuria, infection, or steroid dose changes—often at least every four to six hours on inpatient pathways when patients are unstable, then loosen once trends flatten and plans are documented.

What electrolyte pattern should trigger urgent review in a patient with suspected hyperaldosteronism from ACC?

Marked hypokalaemia with alkalosis or symptomatic arrhythmia in this context warrants senior review and telemetry-aligned care while teams correct potassium under protocol and investigate mineralocorticoid-driven disease.

Why must perioperative steroid instructions differ between ACC patients on chronic mitotane and those who were hormonally silent?

Mitotane chronically suppresses cortisol production so abrupt withdrawal without stress-dose plans risks perioperative collapse, while clinically non-functional tumours still lose a whole adrenal after unilateral resection—teams document explicit glucocorticoid cover for both scenarios rather than copying generic day-case advice.

When should ward staff suspect tumour lysis or marrow suppression during first-line chemotherapy for metastatic ACC?

Fresh cytopenias, fever with neutropenia, rising creatinine, or hyperphosphataemia in the days after cycle one should prompt urgent pathway review and repeat labs—many centres specify surveillance cadences in chemotherapy protocols.

How do imaging choices differ between an adrenal incidentaloma and a mass highly suspicious for ACC?

Incidental lesions often begin with dedicated adrenal CT or MRI characterisation plus hormonal exclusion of benign functional disease, whereas bulky invasive masses or high-grade biochemical suspicion lead to staging cross-sectional imaging and MDT discussion for biopsy versus direct surgical planning per local sarcoma-style pathways.

What nursing documentation best supports safe MDT handoffs for ACC?

Capture dated hormone syndromes, anti-hypertensive or anti-hyperglycaemic titrations, steroid and mitotane administration times, infection screens, pain scores tied to disease sites, and patient-held understanding of emergency contact criteria.

Which symptom cluster most often prompts palliative escalation rather than assuming chronic cancer fatigue alone?

New focal neurology, rapidly worsening jaundice with hepatic capsular pain, uncontrolled vomiting from gastric outlet compression, or sudden dyspnoea from effusion or embolism warrant senior review and often parallel palliative care referral alongside disease-modifying options.

Is biopsy always required before referral for adrenalectomy in apparent localised ACC?

No—many expert pathways reserve percutaneous biopsy for selected unresectable or metastatic presentations because seeding risk and sampling error exist; resection-oriented centres may proceed to en-bloc surgery for highly suspicious imaging after multidisciplinary agreement.

Adrenal Cancer (ACC): Symptoms, Causes, Treatment & Nursing Care | NurseOnShift

🎗️ Oncology · Adrenal cortex

Adrenal Cancer (ACC): Symptoms, Causes, Treatment & Nursing Care

Malignant tumours of the adrenal cortex—functional syndromes, multimodal treatment, steroid safety, and when to escalate.

⏱️25 min read

📅Updated May 1, 2026

✓Medically Reviewed

✍️

Written by

Sid Ahmed Abdala Balal

RGN

🩺

Reviewed by

Nathalie Guerrero Camilo

✨

Featured snippet

Adrenal cancer (adrenocortical carcinoma, ACC) is a rare, aggressive malignancy arising from the adrenal cortex. It may secrete cortisol, sex steroids, or mineralocorticoids—producing dramatic metabolic syndromes—or present as a non-functional abdominal/thoracic mass with local invasion or distant spread.

Clinical snapshot: management centres on expert-pathology diagnosis, complete surgical resection when feasible, mitotane where appropriate, and systemic therapy for advanced disease—always with parallel treatment of hormone excess, infection risk, and perioperative steroid cover.

🔑Key Takeaways

ACC is uncommon—think of it when a large adrenal mass grows quickly, breaches surrounding structures on imaging, or couples with virilisation, severe hypokalaemia, or rapid Cushingoid change.
Functional tumours need concurrent endocrine control (glycaemia, blood pressure, potassium, mood/cognition) while oncology plans proceed—ward teams monitor trends, not single labs.
Staging and MDT documentation usually combine European Network for the Study of Adrenal Tumours (ENSAT) stage, hormone panels, and high-quality cross-sectional imaging; contrast CT and MRI both have roles guided by local radiology.
Curative-intent therapy is radical en-bloc resection where achievable; mitotane or platinum–etoposide–doxorubicin (EDP-M) style regimens enter algorithms for high-risk or metastatic disease per specialist protocols.
After unilateral adrenalectomy or mitotane, patients behave like steroid-vulnerable populations—teams pre-empt hydrocortisone stress dosing and teach adrenal insufficiency warning signs.

⚡ Quick Facts

📊

Incidence

~1–2 per million/yr

⚠️

Functional

~50% secrete hormones*

📍

Metastases

Liver, lung, peritoneum common

⏱️

ENSAT IV cue

Distant disease or R1 resection

*Proportions vary by cohort; functional status guides parallel medical therapy.

💡 Clinical Pearl

Functional clues beat incidental size alone. New severe hypertension with hypokalaemia, virilisation without PCOS context, or accelerated proximal muscle weakness with easy bruising flags cortisol excess from ACC until proven otherwise—and treatment cannot wait quietly for staging scans to finish.

📋 Contents

❓

What is Adrenal Cancer?

In everyday hospital language, “adrenal cancer” usually means adrenocortical carcinoma, a primary epithelial malignancy of adrenal cortical origin rather than metastatic disease seeding the gland or a benign cortical adenoma. Tumour cells retain variable steroidogenic machinery, so some lesions flood the circulation with glucocorticoids, androgens, or mineralocorticoids, while others grow silently until compressive symptoms or systemic spread appear.

Natural history is dominated by locoregional aggressiveness and late metastases. Even after macroscopically complete resection, multidisciplinary teams watch for recurrence because radiological cure is uncommon in high-stage groups without adjuvant strategies. Nurses anchor care on hormone consequences, treatment toxicities, and rapid recognition of sepsis or adrenal collapse when steroid bridges are imperfect.

📊

Staging & ENSAT grouping

ENSAT (European Network for the Study of Adrenal Tumours) staging translates tumour size, invasion beyond the adrenal, nodal involvement, and distant metastasis into four ordinal stages that guide trial eligibility, intensity of mitotane discussion, and surveillance cadence. Pathologists also comment on nuclear grade (for example Ki-67 index) because proliferative markers influence prognosis independent of anatomic stage.

ENSAT stage	Conceptual criteria*	Practice notes
I	Localised, ≤5 cm	Curative surgery focus; discuss adjuvant mitotane per centre policy.
II	Localised, >5 cm	Higher recurrence risk than stage I—tighter imaging follow-up.
III	Local invasion or positive nodes	Often multimodal; scrutinise margin status.
IV	Distant metastases	Systemic therapy, symptom control, clinical trials; meticulous hormone control.

On a small screen, swipe or scroll sideways to see the full table.

*Exact definitions follow the published ENSAT framework—apply the version your tumour board cites because borderline interpretations (e.g., periadrenal fat involvement) change staging calls.

🚨Acute hormone crisis or tumour bleeding—escalate early

Escalate urgently when:

Severe resistant hypertension with confusion, seizures, or chest pain—think uncontrolled cortisol or mineralocorticoid surges.
Sudden hypotension with abdominal pain and falling haemoglobin—possible adrenal haemorrhage or rupture.
Acute pulmonary oedema, marked hyperglycaemia, or new psychosis alongside known functional ACC.

Ward actions: notify oncology/endocrinology senior, ensure two large-bore lines, continuous monitoring, repeat electrolyte panel and glucose, and follow institutional pathways for antihypertensive or steroid rescue dosing rather than ad-hoc titration without consultant input.

🔍

Symptoms

Presentations split between hormone-driven syndromes and mass effects. Because features overlap with common conditions (obesity, depression, primary hypertension), timeline and objective endocrine data separate ACC from mimics.

Hormone-excess patterns

Cushingoid change: proximal weakness, purple striae, hyperglycaemia, infections, mood lability.
Androgen excess: hirsutism, virilisation, libido change—track alongside DHEA-S or androgen panels per protocol.
Mineralocorticoid effect: hypokalaemia, alkalosis, refractory hypertension—align with hypertension symptoms surveillance.

Local or systemic progression

Deep abdominal pain, early satiety, palpable mass, or venous obstruction.
Fatigue, cachexia, or unexplained weight loss disproportionate to intake.

🦠

Causes and Risk Factors

Most ACC appears sporadic. Germline cancer-predisposition variants (for example TP53 in Li-Fraumeni syndrome, Lynch mismatch-repair genes, Beckwith-Wiedemann spectrum) explain a minority but mandate genetic counselling when family or paediatric context fits. Chronic stimulation from an adenoma does not “turn into” ACC often; instead, new radiographic growth or biochemical surges in a previously stable lesion should trigger referral.

Risk-aware practice

Document ionising radiation exposure relevant to field-specific second cancers when constructing histories.
Screen first-degree relatives when known hereditary syndromes surface.

🔬

How is it Diagnosed?

Clinical assessment

Combine tempo of symptoms, hormone phenotype, performance status, and antecedent imaging. Pain assessment scores help quantify visceral progression or bone involvement.

Laboratory investigations

Screens for hypercortisolism (overnight 1 mg dexamethasone suppression where appropriate, late-night salivary cortisol, or 24-hour urinary free cortisol per pathway).
Serum electrolytes, renal panel, and glucose—mirrored in the comprehensive metabolic panel when services bundle tests.
Haematologic baselines: complete blood count and platelet count before mitotane or cytotoxics.

Imaging & pathology

Thin-slice adrenal-protocol CT defines size, fat content, centripetal enhancement, and invasion. MRI helps characterise lipid-poor lesions or venous extension. Expert histopathology (often including IHC) distinguishes ACC from adenoma, pheochromocytoma, or metastasis. Biopsy is not automatic—multidisciplinary tumour boards weigh seeding risk.

🧭

Clinical decision flow

Stabilise critical hormone or metabolic derangements (potassium, glucose, blood pressure, infection).
Confirm diagnosis with imaging + pathology strategy agreed at MDT.
Stage with ENSAT-aligned reporting and document distant sites.
Resect if R0/R1 resection is realistic; otherwise enrol in neoadjuvant or palliative systemic plans.
Adjuvant mitotane or surveillance follows risk strata per published multidisciplinary guidance.
Re-image on defined intervals; escalate early for performance decline or new pain.

🧩

Differential Diagnoses

Entity	Distinguishing notes
Adrenal adenoma	Slow growth, benign imaging signals, mild/absent hormone excess—still merits endocrine evaluation.
Metastasis to adrenal (kidney cancer, melanoma, lung primaries)	Often known primary; imaging may show bilateral deposits; histology confirms.
Pheochromocytoma / paraganglioma	Catecholamine surges with typical spells; different biochemistry and receptor-directed imaging emphasis.
Adrenal haemorrhage / infarction	Acute pain with rapid imaging evolution; lacks malignant mass progression.
Addison's disease	Low cortisol states after contralateral adrenal destruction or surgical overtreatment—opposite biochemical pole unless mixed iatrogeny.

On a small screen, swipe or scroll sideways to see the full table.

💊

Treatment Options

All regimens follow supra-regional protocols; nurses focus on safe delivery, monitoring, and flagging toxicity.

First-line curative pathway

Open or minimally invasive radical adrenalectomy with en-bloc removal of invaded tissue when feasible.
Perioperative stress-dose glucocorticoids even if preoperative cortisol was normal—the remaining axis may be inadequate.

Adjuvant and advanced disease

Mitotane: adrenalolytic agent with narrow therapeutic window—requires therapeutic drug monitoring, neurocognitive surveillance, and gastrointestinal support.
EDP-M (etoposide, doxorubicin, cisplatin) and other combinations per ESMO–EURACAN-era pathways for metastatic disease.
Focal radiation for painful bone or brain metastases when radiotherapy teams agree benefit outweighs toxicity.

⚠️Mitotane interaction vigilance

Mitotane is a potent enzyme inducer—warfarin, opioids, hormonal contraception, and many psychotropics may need dose revision. Pharmacy review on initiation and whenever tablets change strength prevents silent sub-therapeutic anticoagulation or toxicity swings.

📋

Clinical Practice Considerations

Pre-op: document baseline cortisol syndrome severity, optimise potassium, involve anaesthesia early.
Post-op day 0–5: watch for expanding drain output, ileus, wound infection, and need for stress steroid taper schedules.
Surveillance: typical restaging involves cross-sectional imaging every 3–6 months for high-risk cohorts—confirm exact dates in MDT letters.
Mitotane: teach nausea management, dizziness precautions, and when to withhold dose pending drug levels.
Refer sooner if new neuropathy, rising LFTs beyond expected, or cyclical vomiting emerges on therapy.

🏥

Possible Complications

Hormone storm, hypokalaemic arrhythmia, hyperglycaemic hyperosmolar crisis.
Postoperative adrenal insufficiency or iatrogenic crisis if steroid cover stops abruptly.
Venous thromboembolism in prolonged bed rest or hypercortisolism.
Chemotherapy myelosuppression, febrile neutropenia, mucositis.

🛡️

Prevention

There is no population screening analogous to cervical or colorectal programmes. Prevention in practice means genetic counselling for at-risk families, vigilant follow-up when syndromic features emerge, and prompt referral of enlarging adrenal masses or accelerating biochemistry so teams can intervene before unresectable invasion.

📈

Prognosis and Outlook

Outlook depends tightly on stage, margin negativity, Ki-67 index, symptom control, and response to mitotane or chemotherapy. Localised, completely resected disease offers the longest intervals, whereas widespread metastatic ACC still behaves aggressively despite modern combinations—communicate uncertainty honestly while highlighting active trial options.

👩‍⚕️

In Clinical Practice…

Shift work rarely exposes teams to large ACC volumes—lean on tumour board minutes and named clinical nurse specialists for clarifications. Translate dense endocrine jargon into intake/output, orthostatic checks, and medicine times the bedside can action.

✅

Bedside monitoring checklist

Blood pressure (lying and standing when steroid tapering or dehydrated).
Heart rate, temperature, oxygen saturation, pain scores.
Point-of-care or laboratory glucose at clinically appropriate intervals.
Strict intake/output if diuretics or mitotane diarrhoea coexist.
Mental status checks when cortisol swings or opioid doses change.

🚑

When to Seek Emergency Care

Thunderclap headache, focal neurology, or seizure—rule intracranial catastrophe.
Refractory vomiting with abdominal rigidity—surgical review for perforation or haemorrhage.
SpO₂ <92% on previously stable patients, or new pleuritic pain with hypoxia—consider thromboembolism or effusion.

📉

Deterioration & escalation

Invoke the medical emergency or oncology acute pathway when mean arterial pressure drops >20 mmHg below personal baseline despite fluids, potassium falls <3.0 mmol/L with ectopy, glucose exceeds local hyperglycaemic crisis thresholds, or NEWS2 rises sustained. Bring recent drug levels (mitotane), steroid chart, and imaging discs to senior review.

👩‍⚕️

Nursing management

Pre-treatment

Establish vascular access adequate for contrast, resuscitation, and chemotherapy as planned.
Provide culturally competent teaching on hair loss, fertility preservation referrals, and work-leave documentation where relevant.

Active therapy

Anti-emetic timing tied to chemotherapy protocols; mouth care for stomatitis risk.
Infection precautions when neutrophil counts fall—observe neutropenic fever bundles.

Evaluation

Compare weight, grip strength, and sleep quality visit-to-visit as patient-reported outcome proxies.

📚

NCLEX practice questions

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of adrenocortical carcinoma evaluation (functional vs non-functional, imaging features, ENSAT staging), peri-operative steroid management and mitotane stewardship.

Unfolding case (Questions 1–3): Ms. W., 38, presents with 4 months of weight gain, central obesity, easy bruising, hirsutism and new hypertension (BP 172/104). Investigations show 24-hour urinary cortisol 4× ULN, suppressed ACTH and a heterogeneous 8 cm right adrenal mass with central necrosis and irregular margins. Hormonal workup also shows elevated DHEAS. Adrenocortical carcinoma is suspected; she is being prepared for specialist surgery.

Question 1 · Type 1 — MCQ · Family A (Priority — FIRST)

What should the nurse do FIRST for Ms. W. in pre-operative care?

Send for image-guided biopsy of the adrenal mass. Prepare for complete en-bloc surgical resection at a high-volume centre with a fully assessed steroid-replacement plan, optimised BP control (often spironolactone / amiloride and alpha-blocker if any pheochromocytoma feature), glycaemic control, VTE prophylaxis, and cross-disciplinary endocrine, oncology and anaesthetic input. Discharge for observation in primary care. Start chemotherapy alone without surgical referral.

Question 2 · Type 2 — SATA · Family C (Select all that apply)

Which features support adrenocortical carcinoma rather than benign adrenal adenoma? Select all that apply

Mass size >4–6 cm or rapid growth on serial imaging. Heterogeneous appearance with necrosis, calcification and irregular margins. Unenhanced CT density >10 Hounsfield units with delayed washout <40–50%. Small (<1 cm), homogeneous, low-density mass with rapid washout. Combined cortisol and androgen excess (mixed hormonal pattern). Local invasion or distant metastasis at presentation.

Question 3 · Type 2 — SATA · Family E (Deterioration / change in status)

Trend at week 6 post-adrenalectomy: Pre-op — cortisol excess, BP 172/104, glucose 12. Post-op week 6 (on hydrocortisone replacement) — BP 88/52, HR 122, fatigue, dizziness, vomiting, Na⁺ 128, K⁺ 5.5, glucose 3.4.

Which features should prompt the nurse to escalate urgently? Select all that apply

Hypotension and tachycardia. Hyponatraemia with hyperkalaemia (mineralocorticoid signal). Hypoglycaemia. Mild residual surgical pain only. Suspected adrenal crisis from inadequate hydrocortisone (especially during intercurrent illness). Need for IV hydrocortisone bolus, isotonic fluids and rapid endocrine review.

Question 4 · Type 1 — MCQ · Family F (Multi-patient triage — Who first?)

An endocrine-surgical nurse takes report. Which patient should be assessed FIRST?

A patient 6 weeks post-adrenalectomy with BP 88/52, hyperkalaemia, hypoglycaemia and vomiting. A stable patient at routine 6-month ACC oncology review. A patient on long-term mitotane with stable side effects. A patient at preoperative clinic for adenoma resection.

Question 5 · Type 4 — Ordered response · Family H (Ordered response)

Place the workup steps for newly suspected adrenocortical carcinoma in the correct order (1 = first).

Comprehensive history and examination focusing on rapid-onset Cushingoid features, virilisation / feminisation, hypertension and weight loss.
Full hormonal workup (24-h urinary cortisol, dexamethasone suppression, ACTH, plasma metanephrines to exclude pheochromocytoma, androgens / estrogens, aldosterone-renin) before any imaging-guided procedure.
Cross-sectional imaging (contrast CT or MRI of adrenals + chest, FDG-PET in select cases) for size, density, washout and metastatic disease; ENSAT staging.
Refer to a specialist endocrine-oncology centre for complete en-bloc surgical resection by a high-volume surgeon; adjuvant mitotane (± chemotherapy / radiotherapy) for high-risk features.
Lifelong endocrine surveillance (steroid replacement, hormonal recurrence markers, cross-sectional imaging) and structured follow-up with patient steroid-emergency education.

Question 6 · Type 8 — Matrix · Family G (Matrix / matching)

For each scenario, select the most appropriate initial nursing pathway emphasis.

Scenario	Continue routine monitoring / supportive care	Notify clinician / urgent same-day pathway	Activate rapid response / emergency escalation
Stable patient on long-term mitotane and steroid replacement, no symptoms
ACC patient with mitotane GI toxicity, weight loss and rising LFTs
ACC patient with hypotension, hypoglycaemia, hyperkalaemia and vomiting (suspected adrenal crisis)
Patient at routine 3-monthly oncology surveillance imaging, no recurrence

On a small screen, swipe or scroll sideways to see the full table.

Answer key & rationale

Continue practice More endocrine oncology NCLEX drills on NurseOnShift

Adrenal Cancer (ACC): Symptoms, Causes, Treatment & Nursing Care

Featured snippet

⚡ Quick Facts

💡 Clinical Pearl

📋 Contents

What is Adrenal Cancer?

Staging & ENSAT grouping

Symptoms

Hormone-excess patterns

Local or systemic progression

Causes and Risk Factors

Risk-aware practice

How is it Diagnosed?

Clinical assessment

Laboratory investigations

Imaging & pathology

Clinical decision flow

Differential Diagnoses

Treatment Options

First-line curative pathway

Adjuvant and advanced disease

Clinical Practice Considerations

Possible Complications

Prevention

Prognosis and Outlook

In Clinical Practice…

Bedside monitoring checklist

When to Seek Emergency Care

Deterioration & escalation

Nursing management

Pre-treatment

Active therapy

Evaluation

NCLEX practice questions

Answer key & rationale

How often should nurses repeat blood pressure and glucose monitoring when cortisol excess is suspected before endocrine review?

What electrolyte pattern should trigger urgent review in a patient with suspected hyperaldosteronism from ACC?

Why must perioperative steroid instructions differ between ACC patients on chronic mitotane and those who were hormonally silent?

When should ward staff suspect tumour lysis or marrow suppression during first-line chemotherapy for metastatic ACC?

How do imaging choices differ between an adrenal incidentaloma and a mass highly suspicious for ACC?

What nursing documentation best supports safe MDT handoffs for ACC?

Which symptom cluster most often prompts palliative escalation rather than assuming chronic cancer fatigue alone?

Is biopsy always required before referral for adrenalectomy in apparent localised ACC?

Related Clinical Library

Liver Cancer

Lung Cancer

Thyroid Cancer

PET Scan

IV Infusion Pump Setup

Methylprednisolone